Royalty Report: Drugs, cardiac, Disease – Collection: 194318

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • cardiac
  • Disease
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 194318

License Grant
The amendment extends the exclusive license to market, promote and commercialize tadalafil.
License Property
The licensed product tadalafil is solely under the brand name Adcirca®.

U.S. Patent Nos. 6,821,975 (expiring November 19, 2020) (“975”) and 7,182,958 (expiring April 26, 2020) (“958”)

Field of Use
ADCIRCA (tadalafil), an oral treatment for pulmonary arterial hypertension, is a selective inhibitor of cyclic guanosine monophosphate (cGMP).specific phosphodiesterase type 5 (PDE5).

IPSCIO Record ID: 28029

License Grant
Licensor hereby grants to Licensee an exclusive, non-transferable, sublicenseable license, under the Licensor Know-How and the Licensor Patents, to Develop and Commercialize the Product in the Field in the Territory during the Term. Notwithstanding the foregoing, Licensor may conduct research and other development activities with the Compound including, in connection with Licensor’s Development, manufacture and Commercialization of the Product in Licensor’s Domain; provided that Licensor shall not have the right to conduct any clinical study of the Product in the Field in the Territory.
License Property
Competitive Product shall mean any phosphodiesterase 5 inhibitor.
Compound shall mean the bulk active pharmaceutical ingredient tadalafil.
Pulmonary Arterial Hypertension or PAH shall mean all WHO classifications of pulmonary arterial hypertension identified in the Venice 2003 Revised Classification system.
Protocol H6D-MC-LVGX(f) An Extension Study to Evaluate the Long-Term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension.

Patents
5,859,006, Granted January, 12, 1999

6,821,975, Granted November 23, 2004

7, 182, 958, Granted February 27, 2007

US Application 10/521,393

Field of Use
Field shall mean the treatment, amelioration, and prevention of any and all forms of pulmonary hypertension in humans, including (a) all WHO classifications of pulmonary hypertension in the Venice 2003 Revised Classification system and (b) all forms of pulmonary hypertension secondary to other indications.

IPSCIO Record ID: 277861

License Grant
The parties had each granted to the other exclusive worldwide licenses to their respective intellectual property relating to tadalafil oral film formulation and manufacturing. The companies will jointly undertake further co-development and commercialization of Tadalafil oral film products, and will equally share (50/50) net profits from worldwide product sales.
License Property
Tadalafil oral films are for the treatment of erectile dysfunction.
Field of Use
This agreement pertains to the drug industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.